TMCnet News

Eleven Biotherapeutics Announces Filing of its Annual Report on Form 10-K
[April 15, 2014]

Eleven Biotherapeutics Announces Filing of its Annual Report on Form 10-K


CAMBRIDGE, Mass. --(Business Wire)--

Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission.

A copy of the Annual Report on Form 10-K is available to be viewed or downloaded from the Investors & Media section of the company's website at www.elevenbio.com. Eleven Biotherapeutics stockholders or other interested parties may obtain a hard copy of the Annual Report on Form 10-K, free of charge, by contacting the Investor Relations Department at: 215 First Street, Suite 400, Cambridge, MA 02142, or by email at: [email protected].



About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's therapeutic approach is based on the role of cytokines in diseases of the eye, the Company's understanding of the structural biology of cytokines and the Company's ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.



[ Back To TMCnet.com's Homepage ]